Search

Your search keyword '"Ryunosuke Machida"' showing total 3 results
Start Over Author "Ryunosuke Machida" Publisher wiley
3 results on '"Ryunosuke Machida"'

2. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105

Author

Tomotaka Suzuki, Dai Maruyama, Ryunosuke Machida, Tomoko Kataoka, Noriyasu Fukushima, Nobuyuki Takayama, Rie Ohba, Ken Omachi, Yoshitaka Imaizumi, Masahito Tokunaga, Hiroo Katsuya, Isao Yoshida, Kazutaka Sunami, Mitsutoshi Kurosawa, Nobuko Kubota, Hiroaki Morimoto, Miki Kobayashi, Kazuhito Yamamoto, Yoshihiro Kameoka, Yoshitoyo Kagami, Takayuki Tabayashi, Masaki Maruta, Tsutomu Kobayashi, Shinsuke Iida, and Hirokazu Nagai

Subjects
Cancer Research, Oncology, Hematology, General Medicine
Published
2022
Full Text
View/download PDF

3. Possibility of a risk‐adapted treatment strategy for untreated aggressive adult T‐cell leukaemia‐lymphoma ( <scp>ATL</scp> ) based on the <scp>ATL</scp> prognostic index: a supplementary analysis of the <scp>JCOG</scp> 9801

Author

Ryunosuke Machida, Hirokazu Nagai, Kosuke Toyoda, Kenji Ishitsuka, Dai Maruyama, Kunihiro Tsukasaki, Takuya Fukushima, and Tomohiro Kadota

Subjects
Vincristine, medicine.medical_specialty, business.industry, Hazard ratio, Hematology, Ranimustine, Neutropenia, medicine.disease, Gastroenterology, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Prednisone, 030220 oncology & carcinogenesis, Internal medicine, medicine, Vindesine, business, Etoposide, 030215 immunology, medicine.drug
Abstract

JCOG9801, a randomized phase III trial, reported that vincristine, cyclophosphamide, doxorubicin and prednisone (VCAP); doxorubicin, ranimustine and prednisone (AMP); and vindesine, etoposide, carboplatin and prednisone (VECP) (VCAP-AMP-VECP; mLSG15) showed superior clinical outcomes when compared to cyclophosphamide, doxorubicin, vincristine and prednisone every 2 weeks (CHOP-14; mLSG19) in patients with untreated aggressive adult T-cell leukaemia-lymphoma (ATL). To identify patients who require VCAP-AMP-VECP, we conducted a supplementary analysis of JCOG9801. Overall, 105 patients were included and categorized into low- (n = 44), intermediate- (n = 54) and high-risk (n = 7) groups according to the age-adjusted ATL prognostic index (ATL-PI). We excluded the high-risk group due to small numbers of patients. VCAP-AMP-VECP did not show any superior trend for overall survival (OS) in the low-risk group (hazard ratio: 1·04; 95% confidence interval: 0·54-2·04). Better OS was observed in the intermediate-risk group treated with VCAP-AMP-VECP (hazard ratio: 0·65; 95% confidence interval: 0·36-1·19). In the intermediate-risk group, the VCAP-AMP-VECP arm showed higher complete response rates than the CHOP-14 arm (44·0% vs. 13·8%). The VCAP-AMP-VECP arm in both risk groups exhibited grade 4 thrombocytopenia, while grade 4 neutropenia was only observed in the intermediate-risk group. VCAP-AMP-VECP remains suitable for the intermediate-risk group, whereas its benefits appear modest in the low-risk group.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results